Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Added to Russell 2000® Index
SAN DIEGO , June 25, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been added to the Russell 2000 ® Index, effective as of the open of the market on Monday, June 25, 2018 , following Russell's annual
View HTML
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , June 11, 2018 /PRNewswire/ --   Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common stock at a public offering price of $38.85 per share representing no discount to the last
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO , June 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to
View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO , June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
View HTML
Toggle Summary Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
SAN DIEGO , May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology ( ASCO )
View HTML
Toggle Summary Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
SAN DIEGO , May 30, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York on Friday, June 8 th at 8:30 a.m. ET / 5:30 a.m. PT . Charles M.
View HTML
Toggle Summary Mirati Therapeutics Reports First Quarter Financial Results
SAN DIEGO , May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018 . "We have made significant progress in all of our programs and continue to be encouraged by positive
View HTML
Toggle Summary Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
- Six Partial Responses achieved to date in first 23 evaluable patients receiving the combination of sitravatinib and nivolumab for the treatment of checkpoint inhibitor refractory non-small cell lung cancer -- Tumor reductions observed in 19 of 23 evaluable patients -- 45 patients have been
View HTML
Toggle Summary Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
SAN DIEGO , March 8, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, today reported financial results for the fourth quarter and full-year ended December 31, 2017 . "We made significant progress in our key programs in 2017," said
View HTML
Toggle Summary Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , March 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at three upcoming healthcare conferences. Cowen 38 th Annual Healthcare Conference on Wednesday, March 14 th at 9:20 a.m. ET / 6:20 a.m. PT .
View HTML